ABC | Volume 113, Nº2, Agosto 2019

Artigo Original Oliveira et al Risco cardiovascular na psoríase Arq Bras Cardiol. 2019; 113(2):242-249 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 38. Mikael LR, Paiva AM, Gomes MM, Sousa ALL, Jardim PC, Vitorino PV, et al. Vascular Aging and Arterial Stiffness. Arq Bras Cardiol. 2017;109(3):253-8. 39. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J AmAcad Dermatol. 2006;55(5):829-35. 40. Anandarajah AP, Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol. 2004;16(4):338-43. 41. Costa L, Caso F, D’Elia L, Atteno M, Peluso R, Del Puente A, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31(4):711-5. 42. Balta I, Balta S, Demirkol S, Celik T, Ekiz O, Cakar M, et al. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology. 2014;65(1):74-8. 43. Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187-95. 44. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2010;30(5):1014-26. 45. Shang Q, Tam LS, Yip GW, Sanderson JE, Zhang Q, Li EK, et al. High prevalenceofsubclinical leftventriculardysfunction inpatientswithpsoriatic arthritis. J Rheumatol. 2011;38(7):1363-70. 46. Takeshita J,Wang S, ShinDB, MehtaNN, Kimmel SE, Margolis DJ, et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol. 2015;151(2):161-9. 47. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173-9. 48. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. Evidence-basedRecommendations fortheManagementofComorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the CanadianDermatology-Rheumatology Comorbidity Initiative. J Rheumatol. 2015;42(10):1767-80. 49. Eder L, Chandran V, Gladman DD. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann RheumDis. 2014;73(11):1990-6. 249